Drug resistance in lung cancer

Lung Cancer: Targets and Therapy

Volumn 1, Issue , 2010, Pages 23-36

  Shanker, Manish ^a   Willcutts, David ^a   Roth, Jack A ^a   Ramesh, Rajagopal ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Chemotherapy; DNA damage; Lung cancer; Proteasome; Resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA GLYCOSYLTRANSFERASE; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; NAVELBINE; NOLATREXED; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SUPEROXIDE DISMUTASE; UNINDEXED DRUG;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL PROTECTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; EXPERIMENTAL THERAPY; GENE IDENTIFICATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

EID: 77955125025     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology. 1999;39:361-398.
2. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369-7375.
3. Eastman A, Schulte N. Enhanced Dna-Repair As A Mechanism of Resistance to Cis-Diamminedichloroplatinum(Ii). Biochemistry. 1988;27(13):4730-4734.
4. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Journal of Clinical Investigation. 1997;100(5):1282-1293.
5. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine. 1999;5(6):662-668.
6. Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 1999;14(2):153-168.
7. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resistance Updates. 2003;6(4):169-172.
8. Abe Y, Ohnishi Y, Yoshimura M, et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. British Journal of Cancer. 1996;74(12):1929-1934.
9. Volm M, Mattern J, Samsel B. Overexpression of P-Glycoprotein and Glutathione-S-Transferase-Pi in Resistant Non-Small-Cell Lung Carcinomas of Smokers. British Journal of Cancer. 1991;64(4):700-704.
10. Yabuki N, Sakata K, Yamasaki T, et al. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genetics and Cytogenetics. 2007;173(1):1-9.
11. Robey RW, Shukla S, Finley EM, et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)- mediated transport by the orally administered inhibitor, CBT-1 (R). Biochemical Pharmacology. 2008;75(6):1302-1312.
12. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. In Press, Corrected Proof.
13. Helfrich B, Chan D, Helm K, Ashton M, Bunn PA. 648 Expression of MDR-1, MRP and LRP in human lung cancer cell lines from previously treated and untreated patients, chemosensitivity of the cell lines and effects of modulators on sensitivity. Lung Cancer. 1997;18 (Supplement 1):166.
14. Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. Journal of Cancer Research and Clinical Oncology. 2005;131(6):355-363.
15. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. Journal of the National Cancer Institute. 2000;92(16):1295-1302.
16. Young LC, Campling BG, Cole SPC, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clinical Cancer Research. 2001;7(6):1798-1804.
17. Bessho Y, Oguri T, Ozasa H, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncology Reports. 2009;21(1):263-268.
18. Awasthi S, Singhal SS, Singhal J, Cheng JH, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. International Journal of Oncology. 2003;22(4):713-720.
19. Awasthi S, Singhal SS, Singhal J, Yang YS, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. International Journal of Oncology. 2003;22(4):721-732.
20. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Research. 2005;65(3):991-998.
21. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of A M(R) 110,000 Vesicular Protein in Non-P-Glycoprotein-Mediated Multidrug Resistance. Cancer Research. 1993;53(7):1475-1479.
22. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. American Journal of Pathology. 1996;148(3):877-887.
23. Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. Journal of the National Cancer Institute. 1999;91(19):1647-1653.
24. Dingemans AMC, vanArkOtte J, vanderValk P, et al. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Annals of Oncology. 1996;7(6):625-630.
25. Kasahara K, Fujiwara Y, Nishio K, et al. Metallothionein Content Correlates with the Sensitivity of Human Small-Cell Lung- Cancer Cell-Lines to Cisplatin. Cancer Research. 1991;51(12): 3237-3242.
26. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of Metallothionein Confers Resistance to Anticancer Drugs. Science. 1988;241(4874):1813-1815.
27. Yang M, Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radical Biology and Medicine. 2008;45(6):763-772.
28. Klaassen CD, Liu J, Choudhuri S. Metallothionein: An intracellular protein to protect against cadmium toxicity. Annual Review of Pharmacology and Toxicology. 1999;39:267-294.
29. Hoey JG, Garrett SH, Sens MA, Todd JH, Sens DA. Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma. Toxicology Letters. 1997;92(2):149-160.
30. Masters BA, Quaife CJ, Erickson JC, et al. Metallothionein-Iii Is Expressed in Neurons That Sequester Zinc in Synaptic Vesicles. Journal of Neuroscience. 1994;14(10):5844-5857.
31. Quaife CJ, Findley SD, Erickson JC, et al. Induction of A New Metallothionein Isoform (Mt-Iv) Occurs During Differentiation of Stratified Squamous Epithelia. Biochemistry. 1994;33(23):7250-7259.
32. Hamer DH. Metallothionein. Annual Review of Biochemistry. 1986;55:913-951.
33. Hishikawa Y, Kohno H, Ueda S, et al. Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology. 2001;61(2):162-167.
34. Goulding H, Jasani B, Pereira H, et al. Metallothionein Expression in Human Breast-Cancer. British Journal of Cancer. 1995;72(4): 968-972.
35. Tan Y, Sinniah R, Bay BH, Singh G. Metallothionein expression and nuclear size-in benign, borderline, and malignant serous ovarian tumours. Journal of Pathology. 1999;189(1):60-65.
36. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. British Journal of Cancer. 1999;81(4):712-720.
37. Janssen AML, van Duijn W, Kubben FJGM, Griffioen G, Lamers CBHW, van Krieken JHJM, et al. Prognostic significance of metallothionein in human gastrointestinal cancer. Clinical Cancer Research. 2002;8(6):1889-1896.
38. Theocharis S, Karkantaris C, Philipides T, et al. Expression of metallothionein in lung carcinoma: correlation with histological type and. Histopathology. 2002;40(2):143-151.
39. Hishikawa Y, Abe S, Kinugasa S, et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology. 1997;54(4):342-347.
40. Vandier D, Calvez V, Massade L, et al. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. Journal of the National Cancer Institute. 2000;92(8):642-647.
41. Mattern J, Volm M. Increased Resistance to Doxorubicin in Human Non-Small-Cell Lung Carcinomas with Metallothionein Expression. International Journal of Oncology. 1992;1(6):687-689.
42. Tew KD. Glutathione-Associated Enzymes in Anticancer Drug- Resistance. Cancer Research. 1994;54(16):4313-4320.
43. Awasthi YC, Singh SV, Ahmad H, Moller PC. Immunocytochemical Evidence for the Expression of Gst1, Gst2, and Gst3 Gene Loci for Glutathione- S-Transferase in Human-Lung. Lung. 1987;165(6):323-332.
44. Diilio C, Delboccio G, Aceto A, Casaccia R, Mucilli F, Federici G. Elevation of Glutathione Transferase-Activity in Human-Lung Tumor. Carcinogenesis. 1988;9(2):335-340.
45. Buller AL, Clapper ML, Tew KD. Glutathione S-Transferases in Nitrogen Mustard-Resistant and Mustard-Sensitive Cell-Lines. Molecular Pharmacology. 1987;31(6):575-578.
46. Nakagawa K, Saijo N, Tsuchida S, et al. Glutathione-S-Transferase-Pi As A Determinant of Drug-Resistance in Transfectant Cell-Lines. Journal of Biological Chemistry. 1990;265(8):4296-4301.
47. Linsenmeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG, Woodcock DM. Levels of Expression of the Mdr1 Gene and Glutathione- S-Transferase Gene-2 and Gene-3 and Response to Chemotherapy in Multiple-Myeloma. British Journal of Cancer. 1992;65(3):471-475.
48. Ilizarov AM, Koo HC, Kazzaz JA, et al. Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. American Journal of Respiratory Cell and Molecular Biology. 2001;24(4):436-441.
49. Kinnula K, Linnainmaa K, Raivio KO, Kinnula VL. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. British Journal of Cancer. 1998;77(7):1097-1102.
50. Kinnula VL, PietarinenRuntti P, Raivio K, et al. Manganese superoxide dismutase in human pleural mesothelioma cell lines. Free Radical Biology and Medicine. 1996;21(4):527-532.
51. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and Comparative Oncology. 2008;6(1):1-18.
52. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treatment Reviews. 2007;33(6):565-577.
53. Steffensen KD, Waldstrom M, Jakobsen A. The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer. 2009;19(5):820-825.
54. Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F, Gridelli C. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Current Genomics. 2008;9(4):252-262.
55. Rosell R, Lord RVN, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38(3): 217-227.
56. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Research. 2002;8(7):2286-2291.
57. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Research. 2008;18(1):85-98.
58. Liu A, Yoshioka KI, Salerno V, Hsieh P. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. Journal of Cellular Biochemistry. 2008;105(1):245-254.
59. Preston TJ, Henderson JT, McCallum GP, Wells PG. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2 '-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Molecular Cancer Therapeutics. 2009;8(7):2015-2026.
60. Topping RP, Wilkinson JC, Scarpinato KD. Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling. Journal of Biological Chemistry. 2009;284(21):14029-14039.
61. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, Roy R. Targeting base excision repair for chemosensitization. Anti-Cancer Agents in Medicinal Chemistry. 2008;8(4):351-357.
62. Robertson AB, Klungland A, Rognes T, Leiros I. DNA Repair in Mammalian Cells. Cellular and Molecular Life Sciences. 2009;66(6):981-993.
63. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochemical and Biophysical Research Communications. 2005;331(3):868-880.
64. Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by non-homologous end joining. Dna Repair. 2005;4(6): 639-648.
65. Pastwa E, Poplawski T, Czechowska A, Malinowski M, Blasiak J. Non-homologous DNA end joining repair in normal and leukemic cells depends on the substrate ends. Zeitschrift fur Naturforschung C-A Journal of Biosciences. 2005;60(5-6):493-500.
66. Polischouk AG, Holgersson A, Zong DL, et al. The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non-small cell lung carcinoma cells to DNA double-strand break-induced cell death. Molecular Cancer Therapeutics. 2007;6(8):2303-2309.
67. Friesen C, Uhl M, Pannicke U, Schwarz K, Miltner E, Debatin KM. DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. Molecular Biology of the Cell. 2008;19(8):3283-3289.
68. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA doublestrand break repair pathway choice. Cell Research. 2008;18(1): 134-147.
69. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Science. 2008;99(2):187-194.
70. Niedernhofer LJ, Essers J, Weeda G, et al. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. Embo Journal. 2001;20(22):6540-6549.
71. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. International Journal of Cancer. 2003;105(4):472-479.
72. Hansen LT, Lundin C, Helleday T, et al. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer. 2003;40(2): 157-164.
73. Sigmond J, Backus HHJ, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase over expression. Biochemical Pharmacology. 2003;66(3):431-438.
74. Peters GJ, Backus HHJ, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta-Molecular Basis of Disease. 2002;1587(2-3): 194-205.
75. Lin L, Liu X, Rao Y, Wang W, Wang S, Song S. Detection of gemcitabine-resistant genes expression in lung cancer cell lines using real-time PCR. The Chinese-German Journal of Clinical Oncology. 2008;7(12):682-685.
76. Biswas RS, Cha HJ, Hardwick JM, Srivastava RK. Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-X-L. Molecular and Cellular Biochemistry. 2001;225(1-2):7-20.
77. Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. Bcl-2-mediated drug resistance: Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Journal of Experimental Medicine. 1999;190(2):253-265.
78. Inoue Y, Gika M, Abiko T, et al. Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncology Reports. 2005;13(2):259-264.
79. Los M, Herr I, Friesen C, Fulda S, SchulzeOsthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood. 1997;90(8):3118-3129.
80. Okouoyo S, Herzer K, Ucur E, et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. International Journal of Cancer. 2004;108(4):580-587.
81. Volm M, Mattern J, Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Research. 1999;19(3A):1669-1671.
82. Yang LL, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Research. 2003;63(4):831-837.
83. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Journal of Clinical Oncology. 1999;17(7):2100-2104.
84. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. Journal of Pathology. 2003;200(5):620-626.
85. Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer. 2004;46(3):299-304.
86. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal Growth Factor-Related Peptides and Their Receptors in Human Malignancies. Critical Reviews in Oncology/Hematology. 1995;19(3): 183-232.
87. Bunn PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Seminars in Oncology. 2002;29(5):38-44.
88. Bianco R, Troiani T, Tortora G, Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. EndocrineRelated Cancer. 2005;12:S159-S171.
89. Camp ER, Summy J, Bauer TW, Liu WB, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clinical Cancer Research. 2005;11(1):397-405.
90. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
91. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2004;350(21):2129-2139.
92. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science. 2007;98(12):1817-1824.
93. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043.
94. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2005;352(8):786-792.
95. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Plos Medicine. 2005;2(1):57-61.
96. Leroith D, Werner H, Beitnerjohnson D, Roberts CT. Molecular and Cellular Aspects of the Insulin-Like Growth-Factor-I Receptor. Endocrine Reviews. 1995;16(2):143-163.
97. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology. 2008;19(9):1605-1612.
98. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282(5392): 1318-1321.
99. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3- kinase AKT pathway. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(8):4240-4245.
100. Sos ML, Koker M, Weir BA, et al. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research. 2009;69(8):3256-3261.
101. Zhuang HQ, Wang J, Yuan ZY, Zhao LJ, Wang P, Wang CL. The drugresistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. Journal of Experimental and Clinical Cancer Research. 2009;28.
102. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Research. 2001;61(13):5090-5101.
103. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clinical Cancer Research. 2004;10(2):784-793.
104. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling. 2007;19(10):2003 2012.
105. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. Journal of Pathology. 2003;200(3):336-347.
106. Roche J, Drabkin H, Brambilla E. Neuropilin and its ligands in normal lung and cancer. Neuropilin: from Nervous System to Vascular and Tumor Biology. 2002;515:103-114.
107. Wey JS, Gray MJ, Fan F, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. British Journal of Cancer. 2005;93(2):233-241.
108. Staton CA, Yang Z, Reed MWR, Brown NJ. Bevacizumab resistance in breast cancer: are neuropilins the key? Breast Cancer Research. 2008;10:S38.
109. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-331.
110. Fan SJ, Eldeiry WS, Bae I, et al. P53 Gene-Mutations Are Associated with Decreased Sensitivity of Human Lymphoma-Cells to DnaDamaging Agents. Cancer Research. 1994;54(22):5824-5830.
111. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. Journal of Clinical Investigation. 1999;104(3):263-269.
112. Shelling AN. Role of p53 in drug resistance in ovarian cancer. Lancet. 1997;349(9054):744-745.
113. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. Journal of Clinical Oncology. 1999;17(6):1786-1793.
114. Han EKH, Tahir SK, Cherian SP, Collins N, Ng SC. Modulation of paolitaxel resistance by annexin IV in human cancer cell lines. British Journal of Cancer. 2000;83(1):83-88.
115. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical Cancer Research. 2000;6(9):3719-3728.
116. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clinical Cancer Research. 2003;9(3):1145-1154.
117. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clinical Cancer Research. 1999;5(9):2638-2645.
118. Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT- 11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappa B inhibition. Cancer Research. 2001;61(9):3535-3540.
119. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Research. 1999;59(11):2615-2622.
120. Ogiso Y, Tomida A, Lei SH, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Research. 2000;60(9):2429-2434.
121. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30(+) anaplastic large cell lymphoma. Leukemia. 2007;21(4): 838-842.
122. Chondrogianni N, Gonos ES. Overexpression of proteasome beta 5 subunit increases amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates. Febs Journal. 2005;272:151.
123. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clinical Cancer Research. 2003;9(3):1145-1154.
124. Lu SQ, Yang JM, Song XM, et al. Point mutation of the proteasome beta 5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. Journal of Pharmacology and Experimental Therapeutics. 2008;326(2):423-431.
125. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta 5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489-2499.